APA (7th ed.) Citation

F, B., G, G., E, M., H, Y., M, M., D, S., . . . BJP, H. (2019). Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. The Journal of experimental medicine, 216(4), 966. https://doi.org/10.1084/jem.20181276

Chicago Style (17th ed.) Citation

F, Basheer, et al. "Contrasting Requirements During Disease Evolution Identify EZH2 as a Therapeutic Target in AML." The Journal of Experimental Medicine 216, no. 4 (2019): 966. https://doi.org/10.1084/jem.20181276.

MLA (9th ed.) Citation

F, Basheer, et al. "Contrasting Requirements During Disease Evolution Identify EZH2 as a Therapeutic Target in AML." The Journal of Experimental Medicine, vol. 216, no. 4, 2019, p. 966, https://doi.org/10.1084/jem.20181276.